Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Carlomagno

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Endocrine-Related Cancer|February 13, 2019
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasmsOrnella Affinito, Paolo Salerno, Alfonso D'Alessio, et al.
Haematologica|February 29, 2020
NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in miceAntonella Nai, Maria Rosa Lidonnici, Giorgia Federico, et al.
Oncogene|February 20, 2003
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cellsRoberta Visconti, Filippo Schepis, Rodolfo Iuliano, et al.
Oncogene|May 29, 2003
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinaseFrancesco Andreozzi, Rosa Marina Melillo, Francesca Carlomagno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinaseFortunato Ciardiello, Rosa Caputo, Vincenzo Damiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
BRAF is a therapeutic target in aggressive thyroid carcinomaGiuliana Salvatore, Valentina De Falco, Paolo Salerno, et al.
The American Journal of Pathology|July 28, 2004
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinomaRosa Marina Melillo, Anna Maria Cirafici, Valentina De Falco, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 2026
Mining cancer genomes for copy number alterations identifies glycosylation enzymes as oncogenic driversPranoy Sahu, Francesco Russo, Domenico Russo, et al.
Angewandte Chemie (International Ed. in English)|July 2, 2015
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent PolypharmacologyBrendan Frett, Francesca Carlomagno, Maria Luisa Moccia, et al.
Endocrine-Related Cancer|October 15, 2010
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cellsDonata Vitagliano, Valentina De Falco, Anna Tamburrino, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Endocrine-Related Cancer|February 13, 2019
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasmsOrnella Affinito, Paolo Salerno, Alfonso D'Alessio, et al.
Haematologica|February 29, 2020
NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in miceAntonella Nai, Maria Rosa Lidonnici, Giorgia Federico, et al.
Oncogene|February 20, 2003
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cellsRoberta Visconti, Filippo Schepis, Rodolfo Iuliano, et al.
Oncogene|May 29, 2003
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinaseFrancesco Andreozzi, Rosa Marina Melillo, Francesca Carlomagno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinaseFortunato Ciardiello, Rosa Caputo, Vincenzo Damiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
BRAF is a therapeutic target in aggressive thyroid carcinomaGiuliana Salvatore, Valentina De Falco, Paolo Salerno, et al.
The American Journal of Pathology|July 28, 2004
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinomaRosa Marina Melillo, Anna Maria Cirafici, Valentina De Falco, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 2026
Mining cancer genomes for copy number alterations identifies glycosylation enzymes as oncogenic driversPranoy Sahu, Francesco Russo, Domenico Russo, et al.
Angewandte Chemie (International Ed. in English)|July 2, 2015
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent PolypharmacologyBrendan Frett, Francesca Carlomagno, Maria Luisa Moccia, et al.
Endocrine-Related Cancer|October 15, 2010
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cellsDonata Vitagliano, Valentina De Falco, Anna Tamburrino, et al.
Pageof 7